Literature DB >> 29110762

APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?

Opeyemi A Olabisi1, John F Heneghan2.   

Abstract

Apolipoprotein L1 (APOL1) protein is the human serum factor that protect human beings against Trypanosoma brucei brucei, the cause of trypanosomiasis. Subspecies of T b brucei that cause human sleeping sickness-T b gambiense and T b rhodesiense evolved molecular mechanisms that enabled them to evade killing by APOL1. Sequence changes (termed G1 and G2) in the APOL1 gene that restored its ability to kill T b rhodesiense also increase the risk of developing glomerular diseases and accelerate progression to end-stage kidney disease. To lyse trypanosome parasites, APOL1 forms pores in the trypanosome endolysosomal and mitochondrial membranes, resulting in rapid membrane depolarization. However, the molecular mechanism underlying APOL1 nephropathy is unknown. Recent experimental evidence has shown that aberrant efflux of intracellular potassium is an early event in APOL1-induced death of human embryonic kidney cells. Here, we discuss the possibility that abnormal efflux of cellular potassium or other cations may be relevant to the pathogenesis of APOL1 nephropathy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  African American; Apolipoprotein L1; end-stage kidney disease; focal segmental glomerulosclerosis

Mesh:

Substances:

Year:  2017        PMID: 29110762      PMCID: PMC5726439          DOI: 10.1016/j.semnephrol.2017.07.008

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  35 in total

1.  Proteomics. Tissue-based map of the human proteome.

Authors:  Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

2.  APOL1 variants and kidney disease in people of recent African ancestry.

Authors:  Giulio Genovese; David J Friedman; Martin R Pollak
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

3.  Apolipoprotein L-I is the trypanosome lytic factor of human serum.

Authors:  Luc Vanhamme; Françoise Paturiaux-Hanocq; Philippe Poelvoorde; Derek P Nolan; Laurence Lins; Jan Van Den Abbeele; Annette Pays; Patricia Tebabi; Huang Van Xong; Alain Jacquet; Nicole Moguilevsky; Marc Dieu; John P Kane; Patrick De Baetselier; Robert Brasseur; Etienne Pays
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

4.  Vascular smooth muscle cells contribute to APOL1-induced podocyte injury in HIV milieu.

Authors:  Xiqian Lan; Hongxiu Wen; Moin A Saleem; Joanna Mikulak; Ashwani Malhotra; Karl Skorecki; Pravin C Singhal
Journal:  Exp Mol Pathol       Date:  2015-03-18       Impact factor: 3.362

5.  Protein domains of APOL1 and its risk variants.

Authors:  Xiqian Lan; Hongxiu Wen; Rivka Lederman; Ashwani Malhotra; Joanna Mikulak; Waldemar Popik; Karl Skorecki; Pravin C Singhal
Journal:  Exp Mol Pathol       Date:  2015-06-17       Impact factor: 3.362

Review 6.  The trypanolytic factor of human serum.

Authors:  Etienne Pays; Benoit Vanhollebeke; Luc Vanhamme; Françoise Paturiaux-Hanocq; Derek P Nolan; David Pérez-Morga
Journal:  Nat Rev Microbiol       Date:  2006-06       Impact factor: 60.633

7.  Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines.

Authors:  Lijun Ma; Gregory S Shelness; James A Snipes; Mariana Murea; Peter A Antinozzi; Dongmei Cheng; Moin A Saleem; Simon C Satchell; Bernhard Banas; Peter W Mathieson; Matthias Kretzler; Ashok K Hemal; Lawrence L Rudel; Snezana Petrovic; Allison Weckerle; Martin R Pollak; Michael D Ross; John S Parks; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

Review 8.  Apolipoprotein L1 and Kidney Disease in African Americans.

Authors:  David J Friedman; Martin R Pollak
Journal:  Trends Endocrinol Metab       Date:  2016-03-03       Impact factor: 12.015

9.  APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.

Authors:  Leslie A Bruggeman; Zhenzhen Wu; Liping Luo; Sethu M Madhavan; Martha Konieczkowski; Paul E Drawz; David B Thomas; Laura Barisoni; John R Sedor; John F O'Toole
Journal:  J Am Soc Nephrol       Date:  2016-03-29       Impact factor: 10.121

10.  ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death.

Authors:  Siqin Zhaorigetu; Guanghua Wan; Ramesh Kaini; Zeyu Jiang; Chien-an A Hu
Journal:  Autophagy       Date:  2008-11-23       Impact factor: 16.016

View more
  10 in total

Review 1.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

Review 2.  Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.

Authors:  Kimberly J Reidy; Rebecca Hjorten; Rulan S Parekh
Journal:  Curr Opin Pediatr       Date:  2018-04       Impact factor: 2.856

3.  Racial and health insurance disparities in pediatric acute kidney injury in the USA.

Authors:  Erica C Bjornstad; Stephen W Marshall; Amy K Mottl; Keisha Gibson; Yvonne M Golightly; Anthony Charles; Emily W Gower
Journal:  Pediatr Nephrol       Date:  2020-01-29       Impact factor: 3.714

4.  APOL1 risk variants in kidney transplantation: a modulation of immune cell function.

Authors:  Andrew F Malone
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

5.  Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes.

Authors:  Nidhi Gupta; Xinhua Wang; Xiaohui Wen; Paul Moran; Maciej Paluch; Philip E Hass; Amy Heidersbach; Benjamin Haley; Daniel Kirchhofer; Randall J Brezski; Andrew S Peterson; Suzie J Scales
Journal:  J Am Soc Nephrol       Date:  2020-08-06       Impact factor: 10.121

Review 6.  Apolipoprotein L1 nephropathies: 2017 in review.

Authors:  Jeffrey B Kopp; Hila Roshanravan; Koji Okamoto
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-05       Impact factor: 2.894

7.  Alterations in plasma membrane ion channel structures stimulate NLRP3 inflammasome activation in APOL1 risk milieu.

Authors:  Alok Jha; Vinod Kumar; Shabirul Haque; Kamesh Ayasolla; Shourav Saha; Xiqian Lan; Ashwani Malhotra; Moin A Saleem; Karl Skorecki; Pravin C Singhal
Journal:  FEBS J       Date:  2019-12-02       Impact factor: 5.542

8.  APOL1 at 10 years: progress and next steps.

Authors:  Barry I Freedman; Jeffrey B Kopp; Matthew G Sampson; Katalin Susztak
Journal:  Kidney Int       Date:  2021-03-29       Impact factor: 18.998

9.  RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes.

Authors:  Joseph L Bundy; Blair R Anderson; Ludmila Francescatto; Melanie E Garrett; Karen L Soldano; Marilyn J Telen; Erica E Davis; Allison E Ashley-Koch
Journal:  PLoS One       Date:  2019-06-03       Impact factor: 3.240

Review 10.  The evolving story of apolipoprotein L1 nephropathy: the end of the beginning.

Authors:  Parnaz Daneshpajouhnejad; Jeffrey B Kopp; Cheryl A Winkler; Avi Z Rosenberg
Journal:  Nat Rev Nephrol       Date:  2022-02-25       Impact factor: 42.439

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.